Evotec Results Presentation Deck

evotec Positive outcome of Phase IIb trial (PAGANINI) Statistically significant improvement in 24-hour cough counts per hour over placebo after 12 weeks of treatment²) • Positive outcome in chronic cough regarding efficacy, safety and differentiation³) • Favourable safety and tolerability profile PAGE 25 Positive Phase IIb headline data supports best-in-class potential P2X3 antagonist - eliapixant (BAY1817080) Refractory Chronic Cough (RCC) Cough frequency in Phase lla¹) Mean relative change in hourly cough frequency assessed over 24-hour periods versus placebo Mean relative change in cough frequency versus placebo (%) 35 25 15 5 -5 -15 -25 -35 10% -45 -15% 10 mg p=0.004 200 mg BAY 1817080 dose Vertical lines show 90% credible limits. Duration of treatment was 1 week with each dose of BAY 1817080. -23% 50 mg -25% p=0.002 750 mg Detailed efficacy and safety data will be presented by Bayer at upcoming scientific congress 1) Sources: https://conference.thoracic.org/ Poster presented on the ATS 2020 International Conference Virtual Platform 2) Average hourly cough frequency based on 24-hour sound recordings 3) Source: https://media.bayer.com/baynews/baynews.nsf/id/A3224676255E5482C125872600261CAE?open&ref=irrefndcd RCC* Multiple indications potential Overactive Bladder Others BAYER BAYER Endometriosis neuropathic ... pain,

View entire presentation